前瞻性队列研究比较立体定向体部放疗与手术治疗临床早期(T1a-b;≤20 mm)非小细胞肺癌的长期肺癌特异性生存与全因生存
该前瞻性队列研究比较了临床T1a-bN0M0非小细胞肺癌患者接受手术或立体定向体部放疗(SBRT)后的长期生存。共纳入1115例患者(手术1003例,SBRT 112例),中位随访57.6个月。10年肺癌特异性生存率手术组90% vs SBRT组88%(p=0.55),无显著差异;倾向性评分匹配后全因生存亦无显著差异(p=0.74)。
要点
- 10年肺癌特异性生存率手术组90% vs SBRT组88%,无显著差异(p=0.55)
- 倾向性评分匹配后全因生存联合队列无显著差异(p=0.74)
- SBRT可作为小早期NSCLC的替代治疗选择
核心结论
- 对于小早期NSCLC,手术与SBRT的肺癌特异性生存率均高且无显著差异(p=0.48),倾向性匹配后全因生存亦无显著差异(p=0.74)。
- 作者认为这支持SBRT作为小早期NSCLC的替代治疗选择,尤其在低剂量CT筛查使此类病变日益增多的背景下。
- 作者指出治疗决策受多种因素影响,应基于每位患者的具体情况个体化制定。
研究设计与样本
- 前瞻性队列分析,纳入国际早期肺癌行动计划(I-ELCAP)和早期肺癌治疗研究倡议(IELCART)两个前瞻性队列。
- 共纳入1115例首次原发性临床T1a-bN0M0 NSCLC患者,其中手术1003例,SBRT 112例;I-ELCAP 525例(1992年至2021年),IELCART 590例(2016年至2021年)。
- 中位随访57.6个月,采用Kaplan-Meier分析比较肺癌特异性生存和全因生存,倾向性评分匹配平衡基线人口学和合并症后采用Cox比例风险回归分析。
主要发现
- 10年肺癌特异性生存率手术组90%(95%CI 87%-92%)vs SBRT组88%(95%CI 77%-99%),p=0.55,无显著差异。
- Cox回归显示联合队列肺癌特异性生存无显著差异(p=0.48),I-ELCAP单独分析p=1.00,IELCART单独分析p=1.00。
- 10年全因生存率手术组75% vs SBRT组45%,p<0.0001,有显著差异。
- 倾向性评分匹配后,Cox回归显示全因生存联合队列无显著差异(p=0.74),I-ELCAP单独分析p=1.00,IELCART单独分析p=0.62。
临床怎么用
- 作者认为SBRT可作为小早期NSCLC的替代治疗选择。
- 作者指出治疗决策应基于每位患者的具体情况个体化制定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to compare outcomes of patients with first primary clinical T1a-bN0M0 NSCLC treated with surgery or stereotactic body radiation therapy (SBRT). METHODS: We identified patients with first primary clinical T1a-bN0M0 NSCLCs on last pretreatment computed tomography treated by surgery or SBRT in the following two prospective cohorts: International Early Lung Cancer Action Program (I-ELCAP) and Initiative for Early Lung Cancer Research on Treatment (IELCART). Lung cancer-specific survival and all-cause survival after diagnosis were compared using Kaplan-Meier analysis. Propensity score matching was used to balance baseline demographics and comorbidities and analyzed using Cox proportional hazards regression. RESULTS: Of 1115 patients with NSCLC, 1003 had surgery and 112 had SBRT; 525 in I-ELCAP in 1992 to 2021 and 590 in IELCART in 2016 to 2021. Median follow-up was 57.6 months. Ten-year lung cancer-specific survival was not significantly different: 90% (95% confidence interval: 87%-92%) for surgery versus 88% (95% confidence interval: 77%-99%) for SBRT, p = 0.55. Cox regression revealed no significant difference in lung cancer-specific survival for the combined cohorts (p = 0.48) or separately for I-ELCAP (p = 1.00) and IELCART (p = 1.00). Although 10-year all-cause survival was significantly different (75% versus 45%, p < 0.0001), after propensity score matching, all-cause survival using Cox regression was no longer different for the combined cohorts (p = 0.74) or separately for I-ELCAP (p = 1.00) and IELCART (p = 0.62). CONCLUSIONS: This first prospectively collected cohort analysis of long-term survival of small, early NSCLCs revealed that lung cancer-specific survival was high for both treatments and not significantly different (p = 0.48) and that all-cause survival after propensity matching was not significantly different (p = 0.74). This supports SBRT as an alternative treatment option for small, early NSCLCs which is especially important with their increasing frequency owing to low-dose computed tomography screening. Furthermore, treatment decisions are influenced by many different factors and should be personalized on the basis of the unique circumstances of each patient.
引用
- Henschke CI, Yip R, Sun Q, et al. Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery. J Thorac Oncol. 2023. PMID: 37806384. doi:10.1016/j.jtho.2023.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。